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Abstract
Background: The end of life for cancer patients is the ultimate stage of the disease, and care in this setting is
important as it can improve the wellbeing not only of patients, but also the patients’ family and close friends. As it
is a matter of profoundly personal concerns, patients’ perception of this phase of the disease is difficult to assess
and has thus been insufficiently studied. Nonetheless, caregivers are required to provide specific care to help
patients and to treat them in order to improve their wellbeing during this period.
While tools to assess health-related quality of life (QoL) in cancer patients at the end of life exist in English, to our
knowledge, no validated tools are available in French.
Methods/design: This randomized multicenter cohort study will be carried out to cross-culturally adapt and
validate a French version of the English QUAL-E and the Missoula Vitas Quality Of Life Index (MVQOLI)
questionnaires for advanced cancer patients in a palliative setting. A randomized clinical trial component in
addition to a cohort study is implemented in order to test psychometric hypotheses: order effect and
improvement of sensibility to change.
The validation procedure will ensure that the psychometric properties are maintained.
The main criterion to assess the reliability of the questionnaires will be reproducibility (test-retest method) using
intraclass correlation coefficients. It will be necessary to include 372 patients. The sensitivity to change, discriminant
capability as well as convergent validity will be also investigated.
Discussion: If the cross-cultural validation of the MVQOLI and QUAL-E questionnaires for advanced cancer patients
in a palliative setting have satisfactory psychometric properties, it will allow us to assess the specific dimensions of
QoL at the end of life.
Trial registration: Current Controlled Trials NCT01545921.
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Background
The end of life for cancer patients is the ultimate stage
of the disease. However, in this setting, improving qual-
ity of life (QoL) and the wellbeing of patients should
remain a major concern. Given the profoundly personal
concerns involved, patients’ perceptions of the end of
life are difficult to assess and have therefore been insuf-
ficiently studied. Clinicians, nurses, and other paramedi-
cal personnel are required to provide individualized care
adapted to the end of life in order to improve patients’
QoL and wellbeing [1,2].
Today, there is no consensus to define the time frame
related to the ‘end of life’ of a cancer patient [3]. For
example, depending on the cancer site, the ‘palliative’
* Correspondence: anne-lise.poirier@ico.unicancer.fr
1Centre d’Evaluation Clinique en Oncologie, Centre Paul Papin, Angers,
France
Full list of author information is available at the end of the article
Poirier et al. Trials 2012, 13:39
http://www.trialsjournal.com/content/13/1/39 TRIALS
© 2012 Poirier et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.period could vary from a few days to a few months.
Moreover, the palliative and ‘end-of-life’ periods could
overlap, but the therapeutic goals for these two periods
should not be the same. In order to provide optimal
care, it seems crucial to distinguish between these two
periods as the former has a more therapeutic goal while
the latter is to accompany patients as they near death.
This ultimate stage of disease could require caregivers
to meet new demands not only from patients, but also
from their relatives.
To our knowledge (Patient Reported Outcome and
Quality Of Life Instruments Database) [4-6] there are
no French validated tools to assess health-related QoL
for cancer patients at the end of life. QoL is a major
endpoint to assess therapeutic strategies in cancer
patients, particularly in a palliative setting when no ben-
efits in overall survival can be expected. In this context,
QoL should be considered the primary endpoint for
trials [7,8].
QoL at the end of life could be evaluated using gen-
eric QoL questionnaires like EORTC QLQ-C30 and/or
the Medical Outcome study Short Form 36 (SF-36) or
by using questionnaires focusing on symptoms. For
example, the Edmonton Symptoms Assessment System
(ESAS) is a dedicated tool to assess pain [9]. Other tools
allow caregivers to assess depression [10] or fatigue [11].
Some studies have highlighted the fact that additional
specific items could be required to take into account the
most important QoL dimensions or symptoms at the
end of life such as symptom and pain management
[12-16], quality of care [15,16], preparation for death
[12,13], relationships/communication [12-14], family
context [16], dignity [12,16], choice and control [12] the
financial aspect of care [17,18], completion [18], or spiri-
tuality/transcendence [14-16,18].
Current tools to assess QoL do not explore these spe-
cific dimensions, which could capture major aspects of
QoL at the end of life.
Some questionnaires dedicated to the palliative setting
have been proposed, but they are too long, and\or speci-
fic domains related to the end of life are not explored.
Validated QoL tools in French are even more restricted;
only the Mc Gill [19,20] Support Team Assessment
Schedule (STAS) [21] and QLQ-C15 PAL questionnaires
(shortened version of QLQ-C30) [22] are available.
Moreover, these tools are more specifically dedicated to
the palliative setting.
The Missoula-Vitas Quality Of Life Index developed
by Byock et al. has been specifically designed for the
end of palliative setting [14]. This QoL tool provides an
exhaustive assessment of major dimensions in that set-
ting. The shortened version included only 15 items
investigating five dimensions: symptoms, function, inter-
personal relationships, wellbeing, and transcendence
[14]. Another tool, the QUAL-E, is longer and includes
25 items that investigate five domains: life completion,
relations with the healthcare system, preparation for end
of life, symptom severity, and affective social support
[18]. However, these QoL tools have not been adapted
to French culture and translated into French. Another
concern is that they are not specific to cancer patients.
The first step to improve evaluations of how French
patients perceive this disease setting is to translate the
available specific ‘end-of-life’ QoL tools. Assessing QoL
at the end of life with dedicated tools could help to
compare therapeutic strategies and could improve care
in the palliative setting. Based on these hypotheses, we
propose to adapt QoL tools dedicated to the end of life
to French culture and to validate them for French can-
cer patients.
Methods
Objectives
Primary objectives are: to cross-culturally adapt the Eng-
lish questionnaires QUAL-E and MVQOLI (Missoula
Vitas Quality Of Life Index) and to validate their psy-
chometric properties in the end-of-life setting.
Intermediate objectives are: to translate and adapt the
English version of QUAL-E and MVQOLI into French
taking into account cultural differences.
Secondary objectives are: to longitudinally assess QoL
of cancer patients until death using the QLQ-C15 PAL,
the French version of QUAL-E and the Missoula Vitas
Quality of Life Index (MVQOLI); to assess the impact
of therapeutic strategies onQ o La tt h ee n do fl i f e ;t o
assess the added value of spontaneous completion of
QoL questionnaires to detect a clinically significant
change in this setting; to assess the effect of the order of
questionnaires on QoL levels; to define a time period for
the ‘end of life’.
Primary outcomes for cross-cultural and psychometric
validation (see also statistical methods): reproducibility
of QoL scores estimated by intraclass correlation coeffi-
cients; sensitivity to change estimated by effect size and
the standard error of mean; discriminant capability; and
convergent validity.
Study design
We propose to perform a prospective multicenter
cohort study. A randomized clinical trial component in
addition to a cohort study is implemented in order to
test psychometric hypotheses related to order effect and
to the improvement of sensibility to change. This study
has been designed in accordance with the validation
methods of the FDA and the International Society For
Pharmacoeconomics and Outcomes. It was reviewed by
a national patients’ committee in July 2009. The Clinical
trial was registered to the French Safety Agency for
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in France). Although this study does not assess health
products, it was registered as biomedical research. The
authorization was in agreement with the Article L.
1123-8 Code of Public Health and was obtained in Feb-
ruary 2010.
This clinical trial was registered at AFSSAPS (2010-
A00196-33). The project was approved by the local
ethics committee (CPP Ouest II Angers) in April 2010.
The Study was registered in March 2012 on Clinical-
Trials.gov; the registration number is NCT01545921.
The project received a grant so-called PHRC (Pro-
gramme Hospitalier de Recherche Clinique 2011) in
2011 from the French national cancer institute (INCa,
Institut National du Cancer).
Population
To be eligible, patients should have been diagnosed with
advanced cancer (with any cancer site) and treated or
not with palliative intent (chemotherapy, analgesic
radiotherapy, surgery without curative intent), with an
ECOG or a WHO performance status ≥ 2, a life expec-
tancy ≥ 1 month, and an age ≥ 18 years.
Patients should have been informed about the pallia-
tive stage of the disease and should have been followed
for at least 1 month by a palliative caregiver to be
included in the study.
The non-eligibility criteria are: a psychiatric disease
that compromises understanding of the study objectives
and/or informed consent and/or the inability of patients
to follow the study design for psychological, social,
family, or geographical reasons.
Written informed consent is required before inclusion.
Recruitment
Once eligibility criteria have been checked, patients from
French comprehensive cancer care centers or hospitals
will be invited to join the study.
Before inclusion, patients should read and understand
the study information letter and then should date and
sign the informed consent form (ICF) to allow them to
join the study.
The coordinating center will be notified of each inclu-
sion before completion of the first QoL questionnaire
(inclusion document will be completed and returned to
Paul Papin Center, Angers by fax).
Since eligibility criteria will be checked and patients’
ICF will be collected, the first QoL questionnaires and
the test-retest (3 days after the first completion) will be
completed (before randomization) in the following
order: QLQ-C15 PAL, MVQOLI, and QUAL-E.
After completion of the retest QoL questionnaire, the
eligibility criteria and date of signed informed consent
will be collected on a dedicated internet site to allow e-
randomization with a personal log-in and password
(Tenalea software). The study coordinator will then be
able to randomize patients. The allocated arm will be
sent to investigators, to the methodologists, the principal
investigator and the coordinating center by email.
Patients will be randomized after the test-retest to
limit the number of non-assessable patients for
reproducibility.
Randomization
To explore secondary objectives 3 and 4 using a factor-
ial design, QoL questionnaire order, and spontaneous
QoL completion will be randomized 1:1:1:1 using a
minimization technique stratified according to center,
cancer location, sex, and age.
Patients will be randomized in one of the following
four arms (Table 1): (1) Arm A: MVQOLI then QLQ-
C15 PAUL and QUAL-E, evaluation every month; (2)
Arm B: QLQ-C15 PAL, MVQOLI and QUAL-E, evalua-
tion every month; (3) Arm C: MVQOLI then QLQ-C15
PAL and QUAL-E, evaluation every month and sponta-
neous QoL completion; and (4) Arm D: QLQ-C15 PAL,
MVQOLI and QUAL-E evaluation every month and
spontaneous QoL completion.
The above randomization was chosen to explore
methodological aspects to optimize QOL tools in the
end-of-life setting.
It will allow us to assess the occurrence of an order
effect on QoL level by investigating a halo effect and/or
a framing effect. Since every patient should complete
three questionnaires (MVQOLI, QUAL-E, and the
QLQ-C15 PAL), completion of the first questionnaire
could influence responses for the following question-
naires, resulting in different QoL levels. Moreover, this
effect could be differential depending on the completion
o r d e r .S i n c eQ U A L - En e e d saf a c et of a c ei n t e r v i e w ,i t
will be completed by the patient at the end for each
arm.
The second randomization will investigate the added
value of spontaneous QoL completion to capture clini-
cally important changes in QoL that could have
occurred between two planned QoL assessments.
For each allocated group a specific case report form
(CRF) will be produced with the corresponding order of
QoL questionnaires to prevent changes in completion
order (that is, ‘cross-over’) after the randomization.
Furthermore, the date and time of completion for each
QoL questionnaire will be collected. This will allow us to
check the order of completion used by the patients.
Evaluation criteria
End of life QoL questionnaires
Within the framework of this study, three questionnaires
will be used: QLQ-C15 PAL, QUAL-E, and MVQOLI.
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assesses the QoL during a short period (quality of life
during the 2 days before questionnaire completion).
The EORTC QLQ-C15 PAL reflects patients’ QoL
during the previous week and investigates two domains
(symptoms and physical functioning). An additional
item assesses patients’ perception of overall QoL. This is
a shortened version of the EORTC QLQ-C30, which
aims to prevent missing QoL data due to patients’
health status. Scores will be calculated using the same
algorithm as that used in the QLQ-C30 methodology
[22]. Scores will therefore range from 0 (poor QoL) to
100 (best QoL). [23,24].
Taking into account the limited number of dimen-
sions investigated by the EORTC QLQ-C15 PAL, we
have selected the QUAL-E and MVQOLI to comple-
ment QoL evaluations at the end of life. These two
questionnaires dedicated tot h ee n do fl i f eh a v eb e e n
methodologically validated in their original language,
English [25,26].
Twenty-five items and one overall question constitute
the QUAL-E questionnaire. Five dimensions can be
explored: life completion (particularly through contribu-
tions to others), relations with the healthcare system
(knowledge and participation of patients in therapeutic
decisions), preparation for the end of life, symptom
severity (by capturing symptom impact), and affective
social support. This questionnaire should be completed
during a face-to-face interview. Every question is scored
on a 5-point Likert scale [25,26].
The MVQOLI, developed by Byock et al. in 1995
[14,26], includes 15 items in the shortened version and
25 items in the original version. The shortened version
was selected since Byock et al.p r e v i o u s l ys h o w e da
good correlation (r = 0.93) between these two versions,
suggesting that the shortened version does not seem to
be associated with a loss of information [14]. This tool
explores five dimensions: symptoms (experience of the
physical discomfort associated with progressive disease),
functional activities (perceived ability to perform usual
functions and activities), interpersonal (degree of invest-
ment in personal relationships and the perceived quality
of one’s relations with family and friends), wellbeing
(contentment or lack of contentment with self), and
transcendence (degree of experienced meaning and pur-
pose in life). It helps professionals to identify factors
that affect patient QoL at the end of life. The items
related to the ‘evaluation’ range from -2 to +2, those for
the ‘satisfaction’ range from -4 to +4 and those for
‘importance’ range from 1 to 5. Each dimension of the
questionnaire will be calculated using specific items
related to’satisfaction’, ‘evaluation’, and ‘importance’.
The score is the sum of the ‘evaluation’ and ‘satisfac-
tion’ scores multiplied by the ‘importance’ score. The
total score is obtained by summing each score related to
each dimension divided by 10 and then adding 15
Table 1 Follow-up for QoL and data collection according to randomized arms
Baseline Follow-up
D1
a Between
D1 and
D3
b
Before every consultation until
death (J30+/-3 days)
If necessary according to randomized
allocated arm (notebook)
Collected data and order of administration
for QoL questionnaires
Arms Arms Arms Arms
Consent A/B/
C/D
Questionnaires: QLQ-C15, MVQOLI and QUAL-
E
A/B/
C/D
A/B/C/D B and D
Questionnaires: MVQOLI, QLQ-C15 and QUAL-
E
A and C
Questionnaires: MVQOLI, QLQ-C15 D and C
Performance Status, Performance Palliative
Scale
A/B/
C/D
A/B/C/D A, B, C, D
Vital signs, pain (EVA) A/B/
C/D
A/B/C/D A, B, C, D
Care (Oncology, Psychology, and so on) A/B/
C/D
A/B/C/D A, B, C, D
Responsiveness question A/B/
C/D
A/B/C/D D and C
aD1: First day, the day where the first QoL questionnaires will be completed; D3: 3 days after the first day administration
bCan be done D1 at the end of the day if the first was done early in the day
cOnly MVQOLI and QUAL-E
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reflects the impact of each dimension for patients.
Completion of QoL questionnaire
The QoL questionnaires will be completed before ran-
domization and then every month until death in a time
driven design fashion.
Using test-retest methodology, the QLQ-C15 PAL,
MVQOLI, and QUAL-E questionnaires will be com-
pleted 3 days after the first completion at baseline and
before randomization [27].
Though a maximum delay of 15 days is usually
allowed between completions to check reproducibility,
s i n c et h e s ep a t i e n t sh a v eas p e c i f i ce n d - o f - l i f ep r o f i l e
with sometimes a rapid deterioration in general health
status, a maximum delay of 3 days was chosen to mini-
mize the ‘risk’ of changes in health status.
Since the QUAL-E questionnaire should be completed
using a direct interview; patients should complete it last
to prevent social desirability bias on QLQ-C15 PAL and
MVQOLI evaluations [27].
In order to prevent missing QoL data [28], if a patient
is unable to complete questionnaires due to poor health
status, QLQ-C15 PAL and MVQOLI could be com-
pleted with the help of a proxy (from the medical team)
who will have to record the patient’sa n s w e r sw i t h o u t
interpretation [29]. A specific item will be completed to
take this information into account for the longitudinal
analysis of QoL.
All patients will complete QoL questionnaires every
month until death.
In arms C and D, depending on patients’ health status
or perceived QoL, patients will be free to complete the
QLQ-C15 PAL and MVQOLI questionnaires (sponta-
neous QoL completion in an event drive design)
between two planned evaluations. A patient CRF includ-
ing QLQ-C15 PAL and MVQOLI questionnaires, the
date of completion, the perception of QoL changes
using the Jaescke transition question [30]), and a space
for free comments will be created. This booklet will be
given to the patients after randomization.
The QoL questionnaires will be administered in a
homogeneous way by the same person, a nurse specia-
lized in palliative care, a psychologist, or if necessary a
clinical research assistant (CRA), throughout the patient
follow-up until death.
Completed questionnaires should be returned to one
of the CRAs assigned to the study. In order to deal with
holidays, a minimum of two full-time CRAs will be
required and identified for each participating center
(Table 2).
Original CRF and QoL questionnaires will be kept by
the Paul Papin Center; while a copy will be kept on site.
Postal delivery could be allowed.
If a patient does not want to or cannot complete QoL
questionnaires, a note will be made on the unfilled
questionnaire with a brief explanation. An item to col-
lect reasons for non-completion should be also com-
pleted by CRAs.
Other data will be collected: demographic data, medi-
cal history, medical follow-up (social, psychological,
pain, cancer treatment), clinical status, and Jaeschke
transition question to define minimal clinically impor-
tant difference for patients in this setting [30].
Methodology
Translation of the English questionnaire
First step
The QUAL-E and MVQOLI were translated between
May 2010 and July 2010 by the national ‘Qualité de vie
et cancer’ clinical research platform which had selected
national experts to perform this initial step. A transla-
tion group (eight persons) including methodologists, lin-
guists, psychologists, and practitioners in palliative care
was created.
The translation into French and validation of the Eng-
lish-language QUAL-E and MVQOLI questionnaires
were not done using backwards translations. Some stu-
dies underlined that backwards translation methods
could generate a ‘word by word’ translation instead of
fluent, natural, and appropriate language [31].
The selected translation process for linguistic valida-
tion included a translation to the target language
(French) made by one translator who was a native Eng-
lish speaker. This allowed us to take into account speci-
fic intercultural validity problems.
Second step
Before initiating the prospective study, a pre-test will
be done in 30 patients to check this translation. Particu-
lar attention will be paid to collecting data on patients’
u n d e r s t a n d i n go ft h eq u e s t i o n sa sw e l la st h e i r
Table 2 Center’s participation agreement
Organization City
Cancer care center Paul Papin Angers, France
Cancer care center Léon Bérard Lyon, France
Cancer care center Georges François Leclerc Dijon, France
University hospital center Jean Minjoz Besançon, France
Cancer care center Henri Becquerel Rouen, France
Hospital center Cholet, France
Cancer care center Val d’Aurelle-Paul Montpellier, France
Cancer care institute Bergonié Bordeaux, France
Cancer care center Oscar Lambret Lille, France
Cancer care center François Baclesse Caen, France
Cancer care institute curie Paris, France
University hospital center Angers, France
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regarding the QoL questionnaires will be collected.
Furthermore, clinicians specialized in palliative cancer
care will also read and comment the proposed French
translation.
This step is crucial to assess the cultural adaptation
and the weight of the words in this setting. This step is
actually ongoing. Agreements with the investigating cen-
ter have been drafted (November 2010).
Sample size
Primary endpoint
To study the validity of the questionnaires, the selected
primary outcome is reproducibility assessed by intraclass
correlation coefficients (ICC).
Taking into account the number of dimensions for each
QoL questionnaire as well as the number of scores (contin-
uous variable) for which the ICC will be calculated, using
an unilateral alpha type one error of 0.001, a power of 80%
and the following hypotheses (N’Query:Advisor V7):
H0: an ICC < 0.5 is uninteresting
H1: an ICC ≥ 0.65 is the minimum required for
reproducibility
It will be necessary to include 338 patients.
Taking into account that 10% of patients will be lost
to follow-up, it will be necessary to include 372 patients.
Sample size for secondary objectives
The main endpoint to assess the added value of sponta-
neous QoL completion is the proportion of patients
who report at least one Minimal clinically important dif-
ference (MCID) using the Jaeschke transition question.
The minimal clinically important difference is defined
as an improvement or a deterioration of 5% in the theo-
retical QoL score range [23].
With a bilateral alpha type one error of 1% (Bonfer-
roni adjustment for multiple comparisons) a power of
90%, and the following hypotheses:
H0: 70% of patients report an MCID before death in
arms A and B
H1: 90% of patients report an MCID before death in
arms C and D
It will be necessary to have 243 patients with at least
two completed QoL questionnaires between two follow-
ups representing 65.4% of the 372 patients included for
the primary objective.
Statistical analyses
A statistical analysis plan will be written before the data-
base is locked.
The population and clinical characteristics will be
described (sex, age, family situation, cancer site).
The rate of QoL completion will be described for each
questionnaire at each follow-up. QoL scores will be
described at each follow-up.
Continuous variables will be described by means
(standard deviation) and median (minimum-maximum).
Qualitative variables will be described by frequencies
and percentages.
Primary objective analyses
This study will respect the FDA psychometric validation
methods [7].
The first objective is to validate translation of QUAL-
E and MVQOLI by checking the psychometric
properties.
1. Validity [32-34]: Face validity and content validity:
The translated questionnaires will be analyzed by
patients and experts to check that the items of the ques-
tionnaires are in line with to the original version (major
domains treated, question ambiguity). This step was
conducted by the ‘Qualité de vie et cancer’ platform
experts group during cross-cultural translation of the
English questionnaires.
Criterion validity: We will check that the translated
tools correlate with reference QoL or clinical criteria
by calculating correlation coefficients. QLQ-C15 PAL
will be treated as the gold standard for QoL tools. A
strong correlation between the measures given by the
questionnaires and those given by the QLQ-C15 PAL
will constitute proof of criterion validity. We will also
use the WHO performance status and the perfor-
mance palliative scale (PPS). These variables will be
also dichotomized to calculate the sensitivity and spe-
cificity of QoL tools using ROC curves.
Construct validity: This psychometric property will
be checked by calculating establishing convergences
and differences with the other variables. Factorial
analyses as well as Item Response theory methods
will be used.
2. Reliability [32-34]: Effect size and the standardized
response mean will be computed between each follow-
up and then analyzed according to Cohen’s
classification.
Sensitivity to change:
Internal consistency: we will estimate the strength of
the inter-correlations between items, and validate under-
lying dimensions. We will calculate Cronbach’sa l p h aa s
an estimator of this internal consistency for each dimen-
sion of the QoL questionnaires (at each time assess-
ment). This estimator must be greater than 0.7 to
consider a domain homogeneous, but not too close to 1,
which would mean that some questions are redundant.
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using analysis of variance for repeated measurement. An
ICC of 0.65 is the minimum required for reproducibility.
A Bland and Altman graph will be also done [35,36].
Secondary objectives
1. To longitudinally assess QoL of cancer patients until
death using QLQ-C15 PAL, the French version of
QUAL-E, and of Missoula Vitas Quality of Life Index
(MVQOLI) Statistical analyses will be conducted to
investigate longitudinal changes of each QoL dimension:
description of missing QoL scores; missing QoL ques-
tionnaires and scores will be studied and classified
according to Diggle and Rubins’ method to determine
whether the missing data were random or not: Missing
Completely At Random, Missing At Random, Missing
Not At Random [30,31,37,38].
Univariate and multivariate Logistic regression will
be done to construct a clinical model to predict
missing QoL and to investigate the random nature
of missing QoL data. The numbers of missing scores
will be described according to the patient subgroups
a n dc o m p a r e du s i n gA N O V Aa n dM i x e dA n o v af o r
repeated measurement.
Longitudinal analyses
QoL will be described at each follow-up and then longi-
tudinally analyzed using a mixed model analysis of var-
iance for repeated measurements to investigate and test
a time trend for QoL [39-41]:
These models will have to take into account non-ran-
dom missing data.
With simple imputation methods for sensitivity
analyses:
Mean QoL score imputation: Means will be calculated
for the whole population and for specific patient profiles
(cancer location, age, sex, and so on) at each follow-up
and then will be imputed for patients with missing QoL
scores
Extreme QoL score imputation. This method could be
used when the missing data are due to a pejorative
event such as death or disease progression.
With ‘pattern mixture’ models [42,43]:
Qualitative variables will be created to describe miss-
ing QoL score profiles and to define patterns for these
analyses (no missing score, intermittent and drop-out
profiles).
Time until definitive QoL score deterioration:
Analyses of time until a definitive QoL score dete-
rioration (TUDD) will be estimated using the Kaplan-
Meier method [44].
The TUDD of a score will be defined as the time
interval between randomization and the first decrease
in the MCID score ≥ 5 points compared to the QoL
score at inclusion with no further improvement in
QoL score ≥ 5 points or in the case of patient who
dropped out after a ≥ 5-point decrease, resulting in
missing data.
Patients will be censored at the last QoL follow-up
when no ≥ 5-point deterioration in the QoL score from
baseline will be observed or for patients with a ≥ 5-
point deterioration, but with a subsequent ≥ 5-point
improvement as compared to baseline QoL score.
Patients with no available QoL scores will be included
in the TUDD analysis, but censored immediately.
2. To assess the impact of therapeutic strategies on
QoL at the end of life Since treatments and care strate-
gies will be longitudinally collected, for exploratory pur-
poses only, we will compare longitudinal QoL according
to these strategies using mixed model analysis of var-
iance and Log Rank tests and Cox models for the time
to definitive QoL deterioration analyses.
QoL will be described at each follow-up and com-
pared at the inclusion (using Wilcoxon rank test)
and then longitudinally analyzed using mixed model
analyses of variance for repeated measurement
[39-41] to test for the following: a therapeutic strat-
egy effect whatever the follow-up; time effect what-
ever the therapeutic strategy; interactions between
therapeutic strategy and follow-up; and effects of
other clinical factors. The best model will be chosen
according to the smaller Akaike’s information criter-
ion (AIC).
As for the TUDD approach, it will be compared with
Log-Rank tests. Univariate and multivariate Cox ana-
lyses will be done to compute hazard ratios with
95% CI.
3. To assess the added value of spontaneous QoL
completion to detect a clinically significant change in
this setting
The proportion of patients who report at least one
MCID during follow-up using the Jaeschke transition
question will be compared according to the group
allocated by randomization using univariate and
multivariate logistic regressions.
We will also compute effect size (ES) and standar-
dized response mean (SRM) to explore sensitivity to
change according to spontaneous completion of a
QoL questionnaire or not. We aim to demonstrate
that with spontaneous completion of QoL question-
naires, ES and SRM will be improved.
For the sensitivity analysis, time to definitive QoL
deterioration will also be estimated including this
spontaneous completion of QoL questionnaires.
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4. To assess the effect of questionnaire order on QoL
levels Longitudinal QoL analyses will be done as
described above QoL will be described at each follow-up
and compared at inclusion and then longitudinally ana-
lyzed using the mixed model analysis of variance for
repeated measurements [39-41]. For the TUDD
approach, it will be compared with Log-Rank tests. Uni-
variate and multivariate Cox analyses will be done to
compute hazard ratios with 95% CI.
Analyses will be performed on an intent-to-treat
principle.
5. To define a period of ‘end of life’ QoL dimensions
that strongly correlate with a patient’s health status
(physical dimensions, fatigue, pain) should decrease at
the end of life, whereas dimensions (psychological, spiri-
tuality) more related to the end of life could remain
stable and/or could slowly improve. These patterns in
longitudinal QoL changes will be captured using mixed
model analysis of variance for repeated measurement,
and time until definitive QoL score deterioration.
Data management
Data will be collected on CRF. The principal investigator
in each center will be responsible for his or her data.
Then data will be computerized and validated with Cap-
ture System software (Clinsight, Cenon, France) accord-
ing to the specifications defined for this study.
Discussion
The aim of this validation study will be to allow the
assessment of QoL at the end of life in order to improve
care for cancer patients. At this stage of the disease,
patients require the support of clinicians and other care-
givers for discussion, for psychological support and
exchange in order to improve satisfaction and wellbeing.
This support could help patients to cope with the end
of life. Life completion and preparation for death are
essential for patients’ wellbeing and QoL at the end of
life [45]. In this context, an external intervention could
help to improve QoL dimensions, especially dimensions
related to function, emotional status, anxiety, depres-
sion, and preparation for the end of life [46]. Moreover
QoL questionnaires could be used as a communication
tool to facilitate discussion about difficult subjects that
the patient and/or the clinician would not have
approached spontaneously [47]. Furthermore, QoL eva-
luations at the end of life and related discussions could
improve the use of therapies and could contribute to
appropriate care strategies [1,48].
In this context, the absence of validated tools to assess
QoL in French cancer patients at the end of life must
be resolved. This is one of the major preliminary steps
to evaluate QoL in these patients. If our study fails to
confirm the psychometric validity of these translated
tools, we may have to investigate the possibility of creat-
ing a specific QoL tool for French cancer patients at the
end of life.
In this case the creation of a new QoL questionnaire
for French cancer patients at the end of life will be sup-
ported by the ‘Qualité de vie et cancer’ clinical research
platform. This new tool will be developed in agreement
with reference methodology.
We think that these specific questionnaires could be
useful for the evaluation of therapeutic approaches in
future clinical trials or for everyday use in palliative care
units. The ultimate goal should be to improve QoL of
t h e s ep a t i e n t sw h oa r et r y i n gt oc o p ew i t he n d - o f - l i f e
concerns. The perceptions, expectations, and experience
of patients as well as physicians collected during this
study could serve to improve the use of these QoL tools.
Trial status
Between December 15, 2010 and April 5, 2011 30
patients have been included in five centers to check the
understanding of the questions as well as their accept-
ability. Qualitative analyses of these pre-test data con-
firmed that questionnaires and translations were
acceptable and that the study is feasible. Rewording of
some items was the only adjustment needed with
respect to understanding of the translation.
At the time of submission of the manuscript, the long-
itudinal prospective study to cross-culturally adapt the
English questionnaires QUAL-E and Missoula Vital
Quality of Life Index (MVQOLI), and to validate their
psychometric properties in the end-of-life setting is
ongoing. Nine centers were open and active and 12
patients out of the goal of 372 have been included since
November 8, 2011.
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